Argenx
Argenx SE is a global biopharmaceutical enterprise discovering and developing antibody-based therapies for severe autoimmune diseases and rare disorders. The company conducts business operations through a single pharmaceutical segment focused on immunology innovation. Its primary commercialized therapy is efgartigimod, marketed as Vyvgart, approved for treating generalized myasthenia gravis and related auto-immune conditions. Revenue is generated predominantly from commercial prescription sales of Vyvgart through specialty pharmacy networks and healthcare systems globally. The firm holds a market-leading global position in the commercial development of neonatal Fc receptor antagonist therapies. Argenx is headquartered in Breda, Netherlands, with primary operational hubs in Ghent, Belgium, and listings on Euronext Brussels and NASDAQ.
43 of the funds FundTelligence covers report a position in Argenx.
- Legal name
- Argenx SE
- Sector
- Health Care
- Country
- Netherlands
- Funds holding it
- 43
- Exposure themes
- Autoimmune diseases, Treatment, Women's Health
Funds holding Argenx
- DNB Bioteknologi — DNB · 6.91 % (full portfolio disclosed, September 2026)
- Polar Capital Healthcare Opportunities Fund — Polar Capital · 6.2 % (largest positions only, October 2026)
- DNB Fund Women's Health — DNB · 6.01 % (full portfolio disclosed, August 2026)
- Artisan Global Opportunities Fund — Artisan Partners · 4.7 % (largest positions only, September 2026)
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 4.6 % (partially disclosed portfolio, September 2026)
- Janus Henderson Horizon Biotechnology Fund — Janus Henderson · 4.59 % (largest positions only, September 2026)
- Polar Capital Biotechnology Fund — Polar Capital · 4.1 % (largest positions only, October 2026)
- Janus Henderson Horizon Us Sustainable Equity Fund — Janus Henderson · 3.97 % (largest positions only, September 2026)
Showing the 8 largest of 43 funds holding it.